Novartis’ MS therapy Kesimpta wins NICE backing
21st April 2021 Uncategorised 0First self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS
More: Novartis’ MS therapy Kesimpta wins NICE backing
Source: News
First self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS
More: Novartis’ MS therapy Kesimpta wins NICE backing
Source: News
© 1994 - 2026 B.M. Pharmaceuticals